CYP19A1 and breast cancer: The Chinese breast cancer guidelines recommend a combination of CDK4/6 inhibitors and aromatase inhibitors (AI) as the preferred treatment for HR + advanced breast cancer without endocrine therapy, including abemaciclib, palbociclib, ribociclib.